CSL Ltd stock (AU000000CSL8): Shares near nine?year lows after 50% selloff

CSL Ltd shares have lost about half their value over the past 12 months, briefly touching nine?year lows in early May 2026 as investors digest a planned demerger of its flu vaccine business and weaker earnings guidance.

CSL Ltd shares have lost about half their value over the past 12 months, briefly touching nine?year lows in early May 2026 as investors digest a planned demerger of its flu vaccine business and weaker earnings guidance. The stock traded around A$120–A$125 on the Australian Securities Exchange in early May 2026, down roughly 50% from its 12?month peak, according to The Bull as of May 7, 2026. The sharp move reflects a structural reset in market expectations after CSL’s fiscal 2025 results and guidance disappointed investors used to double?digit earnings growth.

As of May 10, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: CSL Limited
• Sector/industry: Biotechnology / biopharmaceuticals
• Headquarters/country: Australia
• Core markets: United States, Europe, Australia and other developed markets
• Key revenue drivers: Plasma?derived therapies, recombinant proteins, vaccines (including influenza)
• Home exchange/listing venue: Australian Securities Exchange (ASX: CSL)
• Trading currency: Australian dollar (AUD)

CSL Ltd: core business model

CSL Ltd is an Australian?based multinational biotechnology company that researches, develops, manufactures and markets biopharmaceutical products and vaccines worldwide. The company operates through three main segments: CSL Behring, which focuses on plasma?derived and recombinant therapies for rare and serious diseases; CSL Seqirus, its influenza vaccine business; and CSL Vifor, which targets kidney?related and iron?deficiency conditions. CSL’s products are used in hospitals, clinics and home?care settings across the United States, Europe, Australia and other developed markets, according to Morningstar Australia as of May 2026.

CSL’s business model centers on high?margin, often life?saving therapies and vaccines that benefit from long?term demand drivers such as aging populations, rising chronic disease prevalence and ongoing need for immunization. The company generates recurring revenue from established plasma?derived products and vaccines, while also investing in new indications and pipeline assets to sustain growth. Its global manufacturing and distribution network allows it to serve both public?health programs and private?pay markets, giving it exposure to both government?funded and commercial healthcare spending.

Main revenue and product drivers for CSL Ltd

CSL’s largest revenue stream comes from CSL Behring, which markets plasma?derived proteins and recombinant therapies for conditions such as bleeding disorders, immune deficiencies and certain neurological diseases. These products typically command premium pricing and benefit from relatively inelastic demand, as many are used to manage chronic, life?threatening conditions. The company also derives significant revenue from CSL Seqirus, one of the world’s leading influenza vaccine suppliers, which sells seasonal flu vaccines to governments, healthcare providers and employers in multiple countries.

In recent years, CSL has expanded its footprint in kidney?related and iron?deficiency therapies through CSL Vifor, adding another growth pillar beyond plasma and vaccines. Together, these segments underpin CSL’s position as one of the largest global biotech companies by market capitalization. However, the company’s growth trajectory has come under pressure as higher interest rates, pricing scrutiny and operational challenges have weighed on margins and earnings, prompting a strategic review that includes a planned demerger of CSL Seqirus and workforce reductions of up to 15%, according to The Bull as of May 7, 2026.

Why CSL Ltd matters for US investors

US investors encounter CSL Ltd primarily through its global biotech profile and its exposure to the large US healthcare market, where many of its plasma?derived therapies and vaccines are sold. The United States is a key revenue region for CSL, and changes in US reimbursement policies, drug?pricing debates and regulatory decisions can materially affect the company’s profitability. At the same time, CSL’s Australian listing means US investors typically access the stock via cross?border brokers or exchange?traded vehicles, adding currency and liquidity considerations to the investment case.

For US?based portfolios, CSL represents a large?cap biotech exposure with a long?standing reputation for innovation and reliability, but also with heightened sensitivity to macroeconomic and policy shifts. The recent 50% share?price decline has drawn attention from value?oriented investors, while others remain cautious about the impact of the planned demerger and restructuring on future earnings and dividend sustainability, according to Motley Fool Australia as of May 10, 2026.

Conclusion

CSL Ltd shares have undergone a sharp correction over the past year, falling roughly 50% from their 12?month peak and briefly touching nine?year lows in early May 2026. The move follows a mixed fiscal 2025 result, weaker earnings guidance and a decision to demerge the CSL Seqirus influenza vaccine business, alongside plans for significant workforce reductions. These developments have prompted a reassessment of CSL’s growth and margin outlook, even as the company continues to generate substantial cash flow and maintain a dividend yield above its historical average.

For investors, CSL remains a large?cap biotech with global reach and exposure to structural healthcare trends, but also with heightened execution and policy risk. The planned demerger and restructuring could unlock value over time, yet they also introduce transitional uncertainty and potential near?term volatility. As with any biotech stock, investors should weigh CSL’s long?term fundamentals against the risks of regulatory change, pricing pressure and macroeconomic headwinds before making any decisions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.